Physician profile
Janet Kim
NPI 1154355857
$9,690.41
in general payments reported to CMS, 2019-2025
34 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $1,084 · 2021: $890 · 2022: $1,677 · 2023: $2,048 · 2024: $1,117 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,069 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,068.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,981.88 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,082.49 | 2019-2025 | |
| Lilly USA, LLC | $1,024.58 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Janssen Biotech, INC. | $936.68 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $868.56 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $748.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $609.92 | 2019-2025 | Benlysta |
| Pfizer INC. | $446.28 | 2019-2025 | |
| Genentech USA, INC. | $209.74 | 2019-2024 | Actemra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.99 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $151.65 | 2019-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $151.38 | 2022-2023 | Arcalyst |
| Sobi, INC | $140.84 | 2019-2020 | |
| Radius Health, INC. | $133.41 | 2020-2024 | Tymlos |
| Janssen Scientific Affairs, LLC | $114.20 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $112.66 | 2019-2025 | |
| Medexus Pharma, INC. | $84.63 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $77.13 | 2019 | |
| Celgene Corporation | $70.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $68.56 | 2019-2020 | |
| Horizon Therapeutics Plc | $67.83 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $65.11 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $63.83 | 2023-2025 | Uzedy, Truxima |
| Takeda Pharmaceuticals U.S.A., INC. | $49.79 | 2022 | |
| Pacira Therapeutics, INC. | $49.37 | 2020-2021 | |
| Emd Serono, INC. | $40.73 | 2023 | Bavencio |
| Merck Sharp & Dohme LLC | $30.41 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $30.29 | 2021-2024 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $29.02 | 2020 | |
| Zyla Life Sciences, INC. | $19.52 | 2019 | |
| Octapharma USA, INC. | $18.40 | 2024 | Octagam Immune Globulin (Human) |
| Kaleo, INC. | $16.38 | 2019 | |
| Shire North American Group INC | $15.01 | 2019 | |
| Alk-Abello, INC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.